{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:02:54Z","timestamp":1788408174070,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-25329-1","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T11:54:17Z","timestamp":1763726057000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Vaccine side effects after vaccination against COVID-19 in employees at an University Hospital in Austria"],"prefix":"10.1038","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct06035926","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0924-2340","authenticated-orcid":false,"given":"Christine Maria","family":"Schwarz-Martelanz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1668-4294","authenticated-orcid":false,"given":"Magdalena","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2533-7067","authenticated-orcid":false,"given":"Andreas","family":"Wedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5187-9105","authenticated-orcid":false,"given":"Andrea","family":"Berghold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5964-4087","authenticated-orcid":false,"given":"Eva","family":"Reininghaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2506-361X","authenticated-orcid":false,"given":"Sabine","family":"Reinisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2966-253X","authenticated-orcid":false,"given":"Andrea","family":"Borenich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6538-3116","authenticated-orcid":false,"given":"Gerald","family":"Sendlhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"25329_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.addr.2020.12.011","volume":"170","author":"JY Chung","year":"2021","unstructured":"Chung, J. Y., Thone, M. N. & Kwon, Y. J. COVID-19 vaccines: The status and perspectives in delivery points of view. Adv. Drug Deliv. Rev. 170, 1\u201325. https:\/\/doi.org\/10.1016\/j.addr.2020.12.011 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"25329_CR2","unstructured":"WHO, \u201cCOVID-19 Vaccine: COVID-19 vaccine tracker and landscape,\u201d https:\/\/www.who.int\/Publications\/M\/Item\/Draft-Landscape-of-Covid-19-Candidate-Vaccines. p. 1. Available: https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines (2022)."},{"issue":"1","key":"25329_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4103\/ijmr.ijmr_1221_21","volume":"155","author":"S Kaur","year":"2022","unstructured":"Kaur, S. et al. Reporting adverse events of ChAdOx1 nCoV-19 coronavirus vaccine (Recombinant) among the vaccinated healthcare professionals: A cross-sectional survey. Indian J. Med. Res. 155(1), 123\u2013128. https:\/\/doi.org\/10.4103\/ijmr.ijmr_1221_21 (2022).","journal-title":"Indian J. Med. Res."},{"issue":"8","key":"25329_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/medicines9080043","volume":"9","author":"RI Oueijan","year":"2022","unstructured":"Oueijan, R. I., Hill, O. R., Ahiawodzi, P. D., Fasinu, P. S. & Thompson, D. K. Rare heterogeneous adverse events associated with mRNA-based COVID-19 vaccines: A systematic review. Medicines 9(8), 43. https:\/\/doi.org\/10.3390\/medicines9080043 (2022).","journal-title":"Medicines"},{"issue":"7","key":"25329_CR5","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1056\/nejmra2035343","volume":"384","author":"MC Castells","year":"2021","unstructured":"Castells, M. C. & Phillips, E. J. Maintaining safety with SARS-CoV-2 vaccines. N. Engl. J. Med. 384(7), 643\u2013649. https:\/\/doi.org\/10.1056\/nejmra2035343 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"25329_CR6","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/ana.26172","volume":"90","author":"JB Schulz","year":"2021","unstructured":"Schulz, J. B. et al. COVID-19 vaccine-associated cerebral venous thrombosis in Germany. Ann. Neurol. 90(4), 627\u2013639. https:\/\/doi.org\/10.1002\/ana.26172 (2021).","journal-title":"Ann. Neurol."},{"issue":"8","key":"25329_CR7","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.3324\/haematol.2021.279000","volume":"106","author":"K Althaus","year":"2021","unstructured":"Althaus, K. et al. Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia. Haematologica 106(8), 2170\u20132179. https:\/\/doi.org\/10.3324\/haematol.2021.279000 (2021).","journal-title":"Haematologica"},{"key":"25329_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-14225-2","author":"N Mongua-Rodr\u00edguez","year":"2022","unstructured":"Mongua-Rodr\u00edguez, N. et al. Knowledge, attitudes, perceptions, and COVID-19 hesitancy in a large public university in Mexico city during the early vaccination rollout. BMC Public Health https:\/\/doi.org\/10.1186\/s12889-022-14225-2 (2022).","journal-title":"BMC Public Health"},{"key":"25329_CR9","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.addr.2021.01.014","volume":"172","author":"S Chakraborty","year":"2021","unstructured":"Chakraborty, S., Mallajosyula, V., Tato, C. M., Tan, G. S. & Wang, T. T. SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?. Adv. Drug Deliv. Rev. 172, 314\u2013338. https:\/\/doi.org\/10.1016\/j.addr.2021.01.014 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"25329_CR10","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.30.20142570v1.abstract","author":"MJ Mulligan","year":"2020","unstructured":"Mulligan, M. J. et al. Phase 1\/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: interim report. medRxiv https:\/\/doi.org\/10.1101\/2020.06.30.20142570v1.abstract (2020).","journal-title":"medRxiv"},{"key":"25329_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.585354","author":"O Sharma","year":"2020","unstructured":"Sharma, O., Sultan, A. A., Ding, H. & Triggle, C. R. A review of the progress and challenges of developing a vaccine for COVID-19. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2020.585354 (2020).","journal-title":"Front. Immunol."},{"key":"25329_CR12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.40878","author":"SMS Haider","year":"2023","unstructured":"Haider, S. M. S. et al. Common side effects of Pfizer COVID-19 vaccine: An experience from Pakistan. Cureus https:\/\/doi.org\/10.7759\/cureus.40878 (2023).","journal-title":"Cureus"},{"issue":"10262","key":"25329_CR13","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1016\/S0140-6736(20)32137-1","volume":"396","author":"GA Poland","year":"2020","unstructured":"Poland, G. A., Ovsyannikova, I. G. & Kennedy, R. B. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. The Lancet 396(10262), 1595\u20131606. https:\/\/doi.org\/10.1016\/S0140-6736(20)32137-1 (2020).","journal-title":"The Lancet"},{"issue":"8","key":"25329_CR14","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S1473-3099(21)00127-4","volume":"21","author":"S Yang","year":"2021","unstructured":"Yang, S. et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect. Dis. 21(8), 1107\u20131119. https:\/\/doi.org\/10.1016\/S1473-3099(21)00127-4 (2021).","journal-title":"Lancet Infect. Dis."},{"issue":"23","key":"25329_CR15","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/nejmoa2101544","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff, J. et al. Safety and efficacy of single-dose Ad26.COV2.S Vaccine against COVID-19. N. Engl. J. Med. 384(23), 2187\u20132201. https:\/\/doi.org\/10.1056\/nejmoa2101544 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"25329_CR16","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/nejmoa2034201","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff, J. et al. Interim results of a phase 1\u20132a trial of Ad26.COV2.S COVID-19 vaccine. N. Engl. J. Med. 384(19), 1824\u20131835. https:\/\/doi.org\/10.1056\/nejmoa2034201 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"10267","key":"25329_CR17","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","volume":"396","author":"MN Ramasamy","year":"2020","unstructured":"Ramasamy, M. N. et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial. Lancet 396(10267), 1979\u20131993. https:\/\/doi.org\/10.1016\/S0140-6736(20)32466-1 (2020).","journal-title":"Lancet"},{"key":"25329_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n699","volume":"372","author":"J Wise","year":"2021","unstructured":"Wise, J. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. BMJ 372, n699. https:\/\/doi.org\/10.1136\/bmj.n699 (2021).","journal-title":"BMJ"},{"issue":"15","key":"25329_CR19","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1056\/nejmoa2114255","volume":"385","author":"YM Bar-On","year":"2021","unstructured":"Bar-On, Y. M. et al. Protection of BNT162b2 vaccine booster against COVID-19 in Israel. N. Engl. J. Med. 385(15), 1393\u20131400. https:\/\/doi.org\/10.1056\/nejmoa2114255 (2021).","journal-title":"N. Engl. J. Med."},{"key":"25329_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0132-6","author":"C Herv\u00e9","year":"2019","unstructured":"Herv\u00e9, C., Laup\u00e8ze, B., Del Giudice, G., Didierlaurent, A. M. & Da Silva, F. T. The how\u2019s and what\u2019s of vaccine reactogenicity. npj Vaccines https:\/\/doi.org\/10.1038\/s41541-019-0132-6 (2019).","journal-title":"npj Vaccines"},{"key":"25329_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10010018","author":"MO Elgendy","year":"2022","unstructured":"Elgendy, M. O. et al. SARS-CoV-2 post vaccinated adverse effects and efficacy in the Egyptian population. Vaccines https:\/\/doi.org\/10.3390\/vaccines10010018 (2022).","journal-title":"Vaccines"},{"key":"25329_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10071428","author":"A Riad","year":"2021","unstructured":"Riad, A. et al. Prevalence of covid-19 vaccine side effects among healthcare workers in the Czech Republic. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm10071428 (2021).","journal-title":"J. Clin. Med."},{"key":"25329_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11040747","author":"G Giannotta","year":"2023","unstructured":"Giannotta, G., Murrone, A. & Giannotta, N. COVID-19 mRNA vaccines: The molecular basis of some adverse events. Vaccines https:\/\/doi.org\/10.3390\/vaccines11040747 (2023).","journal-title":"Vaccines"},{"issue":"7","key":"25329_CR24","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1473-3099(21)00224-3","volume":"21","author":"C Menni","year":"2021","unstructured":"Menni, C. et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect. Dis. 21(7), 939\u2013949. https:\/\/doi.org\/10.1016\/S1473-3099(21)00224-3 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"25329_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/biology10080752","author":"M Klugar","year":"2021","unstructured":"Klugar, M. et al. Side effects of mrna-based and viral vector-based covid-19 vaccines among German healthcare workers. Biology (Basel) https:\/\/doi.org\/10.3390\/biology10080752 (2021).","journal-title":"Biology (Basel)"},{"key":"25329_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.imlet.2022.10.002","volume":"251\u2013252","author":"JJ Morales-N\u00fa\u00f1ez","year":"2022","unstructured":"Morales-N\u00fa\u00f1ez, J. J. et al. Comparison of three different COVID-19 vaccine platforms (CoronaVac, BTN162b2, and Ad5-nCoV) in individuals with and without prior COVID-19: Reactogenicity and neutralizing antibodies. Immunol. Lett. 251\u2013252, 20\u201328. https:\/\/doi.org\/10.1016\/j.imlet.2022.10.002 (2022).","journal-title":"Immunol. Lett."},{"issue":"4","key":"25329_CR27","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1055\/s-0036-1584923","volume":"37","author":"JP Lynch","year":"2016","unstructured":"Lynch, J. P. & Kajon, A. E. Adenovirus: Epidemiology, global spread of novel serotypes, and advances in treatment and prevention. Semin. Respir. Crit. Care Med. 37(4), 586\u2013602. https:\/\/doi.org\/10.1055\/s-0036-1584923 (2016).","journal-title":"Semin. Respir. Crit. Care Med."},{"issue":"4","key":"25329_CR28","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1001\/jama.2021.24110","volume":"327","author":"ME Oster","year":"2022","unstructured":"Oster, M. E. et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA 327(4), 331\u2013340. https:\/\/doi.org\/10.1001\/jama.2021.24110 (2022).","journal-title":"JAMA"},{"key":"25329_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069445","author":"J Pillay","year":"2022","unstructured":"Pillay, J. et al. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following COVID-19 vaccination: living evidence syntheses and review. The BMJ. https:\/\/doi.org\/10.1136\/bmj-2021-069445 (2022).","journal-title":"The BMJ."},{"issue":"10","key":"25329_CR30","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1161\/CIRCRESAHA.122.321881","volume":"132","author":"NL Altman","year":"2023","unstructured":"Altman, N. L. et al. Vaccination-associated myocarditis and myocardial injury. Circ. Res. 132(10), 1338\u20131357. https:\/\/doi.org\/10.1161\/CIRCRESAHA.122.321881 (2023).","journal-title":"Circ. Res."},{"key":"25329_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9121463","author":"O Par\u00e9s-Badell","year":"2021","unstructured":"Par\u00e9s-Badell, O. et al. Local and systemic adverse reactions to mrna COVID-19 vaccines comparing two vaccine types and occurrence of previous covid-19 infection. Vaccines https:\/\/doi.org\/10.3390\/vaccines9121463 (2021).","journal-title":"Vaccines"},{"key":"25329_CR32","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2021.0205","author":"M Ziemann","year":"2021","unstructured":"Ziemann, M. & G\u00f6rg, S. Inability to work after corona vaccination in medical staff. Dtsch. Arztebl. Int. https:\/\/doi.org\/10.3238\/arztebl.m2021.0205 (2021).","journal-title":"Dtsch. Arztebl. Int."},{"key":"25329_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac203","author":"S Bauernfeind","year":"2022","unstructured":"Bauernfeind, S. et al. Health care workers\u2019 sick leave due to COVID-19 vaccination in context with SARS-CoV-2 infection and quarantine: A multicenter cross-sectional survey. Open Forum Infect. Dis. https:\/\/doi.org\/10.1093\/ofid\/ofac203 (2022).","journal-title":"Open Forum Infect. Dis."},{"key":"25329_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07284-8","author":"I Nachtigall","year":"2022","unstructured":"Nachtigall, I. et al. Effect of gender, age and vaccine on reactogenicity and incapacity to work after COVID-19 vaccination: a survey among health care workers. BMC Infect. Dis. https:\/\/doi.org\/10.1186\/s12879-022-07284-8 (2022).","journal-title":"BMC Infect. Dis."},{"issue":"22","key":"25329_CR35","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1001\/archinternmed.2008.513","volume":"168","author":"RJM Engler","year":"2008","unstructured":"Engler, R. J. M. et al. Half- vs full-dose trivalent inactivated influenza vaccine (2004\u20132005): Age, dose, and sex effects on immune responses. Arch. Intern. Med. 168(22), 2405\u20132414. https:\/\/doi.org\/10.1001\/archinternmed.2008.513 (2008).","journal-title":"Arch. Intern. Med."},{"issue":"10","key":"25329_CR36","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","volume":"16","author":"SL Klein","year":"2016","unstructured":"Klein, S. L. & Flanagan, K. L. Sex differences in immune responses. Nat. Rev. Immunol. 16(10), 626\u2013638. https:\/\/doi.org\/10.1038\/nri.2016.90 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"25329_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10122076","author":"ZA Badami","year":"2022","unstructured":"Badami, Z. A. et al. Comparison of general anxiety among healthcare professionals before and after COVID-19 vaccination. Vaccines https:\/\/doi.org\/10.3390\/vaccines10122076 (2022).","journal-title":"Vaccines"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25329-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25329-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25329-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T11:54:20Z","timestamp":1763726060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25329-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["25329"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-25329-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"12 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41353"}}